Ann: Appendix 4D & Half Yearly Report and Accounts, page-48

Just perusing some numbers over the last 24 hours and was surprised to see when I read this thread that no one ever posed the reasons for the high costs for last half of 2018 numbers. When looking at it they are actually very cheap given the circumstances and it's not like hey would be continuing at such high costs.

Think of the costs the last half of 2018
1) Setting up offices and executive staff in US
2) Acquiring production facility
3) Staffing the facility
4) Hiring/training sales staff and ReCell training teams
5) Finishing trials for FDA approval
6) Starting final pediatric trials in US
7) Continuing Chinese trials
8) Final trials for advanced Vitilgo and Scars
9) Getting trials underway for Rejuvenation,trauma wounds and skin diseases like Epidemolysis
10) Increase in burn conferences after FDA approval so none are missed
11) Materials purchased to manufacture ReCell for launch
12) Cost of outfitting sales/training teams the small costs with startups are large as its from ground up.

I am probably missing a lot and remember there is still money left from BARDA to help with the new trials, it was an expensive 6 months but the facility and getting that up and ready with the various teams was no small fete nor was it cheap starting up is expensive. If you use that 22 million number about 15 million after BARDA money and 1st sales you're being overly cautious to say the least, relax you already won.

Peace out.